Radius Health (RDUS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Radius Health, Inc.: Third Quarter 2021 Results
November 8, 2021 8:00 AM ESTTYMLOS® Q3, 2021 net revenue: $57 million, +13% vs. Q3, 2020Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included elacestrant license revenueATOM Pivotal Study evaluating abaloparatide-SC for use in males with osteoporosis met primary and key secondary endpoints; sNDA filing is expected Q1, 2022Resubmitted abaloparatide-SC to the European Medicines Agency (EMA) on November 4, 2021wearABLe Pivotal Study (abaloparatide-TD) topline readout remains on track for Q4, 2021EMERALD Pivotal Study evaluating elacestrant in breast cancer was positive as a monotherapy vs.... More
